Arch Therapeutics, Inc.
ARTH · OTC
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.03 | -0.11 | -53.11 |
| FCF Yield | -84.55% | -96.74% | -20.85% | -0.08% |
| EV / EBITDA | -2.42 | -1.53 | -4.59 | -1,218.99 |
| Quality | ||||
| ROIC | 268.33% | 2,774.58% | -344.45% | -348.24% |
| Gross Margin | -3.22% | -228.96% | -127.25% | 0.00% |
| Cash Conversion Ratio | 0.48 | 0.84 | 0.95 | 1.08 |
| Growth | ||||
| Revenue 3-Year CAGR | 87.08% | – | – | – |
| Free Cash Flow Growth | 24.18% | 25.26% | -18.12% | 4.20% |
| Safety | ||||
| Net Debt / EBITDA | -1.39 | -0.56 | 0.11 | 0.04 |
| Interest Coverage | -1.63 | -10.07 | -42.36 | -298.37 |
| Efficiency | ||||
| Inventory Turnover | 0.06 | 0.04 | 0.02 | 0.01 |
| Cash Conversion Cycle | -4,388.16 | -9,561.23 | -177.27 | 32,987.18 |